Cargando…

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis

BACKGROUND: Primary progressive (PP) multiple sclerosis (MS) is considered a clinically distinct entity from the spectrum of relapsing-remitting (RR) forms of the disease. OBJECTIVE: To compare the presence of brain and spinal cord lesions between PP and RR subjects. METHODS: We studied people with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dastagir, Akram, Healy, Brian C., Chua, Alicia S., Chitnis, Tanuja, Weiner, Howard L., Bakshi, Rohit, Tauhid, Shahamat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141305/ https://www.ncbi.nlm.nih.gov/pubmed/30229136 http://dx.doi.org/10.1016/j.ensci.2018.07.002

Ejemplares similares

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2015)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2018)

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
por: Sotiropoulos, Marinos G, et al.
Publicado: (2021)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

Dual‐Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI
por: Meier, Dominik S., et al.
Publicado: (2017)

An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2016)

Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines
por: Chu, Renxin, et al.
Publicado: (2018)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis
por: Yousuf, Fawad, et al.
Publicado: (2016)

MRI phenotypes in MS: Longitudinal changes and miRNA signatures
por: Hemond, Christopher C., et al.
Publicado: (2019)

Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability
por: Chu, Renxin, et al.
Publicado: (2017)

Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
por: Chu, Renxin, et al.
Publicado: (2016)

Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study
por: Singhal, Tarun, et al.
Publicado: (2019)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
por: Bakshi, Rohit, et al.
Publicado: (2016)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors
por: Dell’Oglio, Elisa, et al.
Publicado: (2015)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
por: Rosso, Mattia, et al.
Publicado: (2020)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
por: Ghezzi, Angelo, et al.
Publicado: (2019)

MRI activity in MS and completed pregnancy: Data from a tertiary academic center
por: Houtchens, Maria, et al.
Publicado: (2020)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases
por: Hemond, Christopher C., et al.
Publicado: (2021)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Negative prognostic impact of MRI spinal lesions in the early stages of relapsing–remitting multiple sclerosis
por: D’Amico, E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mn2jtm421erb1q88a1bsqdjpha